Wall Street analysts expect Genomic Health, Inc. (NASDAQ:GHDX) to announce earnings per share (EPS) of $0.07 for the current fiscal quarter, Zacks Investment Research reports. Six analysts have issued estimates for Genomic Health’s earnings. The lowest EPS estimate is $0.05 and the highest is $0.10. Genomic Health posted earnings of $0.03 per share during the same quarter last year, which suggests a positive year-over-year growth rate of 133.3%. The firm is expected to issue its next quarterly earnings results on Wednesday, November 14th.

According to Zacks, analysts expect that Genomic Health will report full-year earnings of $0.55 per share for the current financial year, with EPS estimates ranging from $0.46 to $0.69. For the next financial year, analysts anticipate that the firm will report earnings of $0.77 per share, with EPS estimates ranging from $0.47 to $0.95. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Genomic Health.

Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings data on Thursday, August 2nd. The medical research company reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of $0.07 by $0.19. Genomic Health had a net margin of 1.18% and a return on equity of 9.09%. The firm had revenue of $95.60 million for the quarter, compared to analyst estimates of $92.23 million. During the same period last year, the firm posted ($0.08) EPS. Genomic Health’s quarterly revenue was up 14.1% on a year-over-year basis.

A number of equities analysts recently weighed in on GHDX shares. Zacks Investment Research upgraded shares of Genomic Health from a “hold” rating to a “buy” rating and set a $67.00 price objective on the stock in a research report on Wednesday. ValuEngine upgraded shares of Genomic Health from a “buy” rating to a “strong-buy” rating in a research report on Thursday, June 7th. Piper Jaffray Companies lifted their price objective on shares of Genomic Health from $34.00 to $50.00 and gave the company a “neutral” rating in a research report on Friday, July 27th. Deutsche Bank lifted their price objective on shares of Genomic Health from $32.00 to $34.00 and gave the company a “hold” rating in a research report on Thursday, May 3rd. Finally, Cowen reiterated a “hold” rating and issued a $50.00 price objective on shares of Genomic Health in a research report on Monday, August 6th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $45.44.

NASDAQ:GHDX opened at $60.70 on Tuesday. Genomic Health has a 1-year low of $26.54 and a 1-year high of $62.25. The firm has a market capitalization of $2.13 billion, a P/E ratio of 119.00 and a beta of 0.49.

In other Genomic Health news, insider Kimberly J. Popovits sold 60,000 shares of the firm’s stock in a transaction on Tuesday, August 14th. The stock was sold at an average price of $52.60, for a total value of $3,156,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Fred E. Cohen sold 8,250 shares of the firm’s stock in a transaction on Tuesday, August 7th. The shares were sold at an average price of $56.22, for a total value of $463,815.00. Following the completion of the sale, the director now directly owns 75,572 shares of the company’s stock, valued at approximately $4,248,657.84. The disclosure for this sale can be found here. In the last three months, insiders sold 206,693 shares of company stock valued at $10,251,425. 45.80% of the stock is owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in GHDX. Deutsche Bank AG raised its stake in shares of Genomic Health by 53.4% during the 4th quarter. Deutsche Bank AG now owns 48,523 shares of the medical research company’s stock worth $1,656,000 after buying an additional 16,883 shares during the last quarter. Algert Global LLC acquired a new position in shares of Genomic Health during the 1st quarter worth $899,000. Mackay Shields LLC acquired a new position in shares of Genomic Health during the 1st quarter worth $417,000. Trexquant Investment LP acquired a new position in shares of Genomic Health during the 1st quarter worth $551,000. Finally, American Century Companies Inc. raised its stake in shares of Genomic Health by 6.6% during the 1st quarter. American Century Companies Inc. now owns 207,340 shares of the medical research company’s stock worth $6,488,000 after buying an additional 12,837 shares during the last quarter. 89.33% of the stock is owned by institutional investors and hedge funds.

About Genomic Health

Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.

Further Reading: How to Invest in Growth Stocks

Get a free copy of the Zacks research report on Genomic Health (GHDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.